{
  "docId": "019de075-adb8-762c-8a34-68ae2626b554",
  "docSlug": "3a94cd37bbc178d56e25705cc2452800",
  "documentTitle": "Legend Biotech | Results Presentation Deck | 16 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 16,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a before-after style transition (Heavily Pre-Treated to Earlier Lines) to frame the expansion strategy.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-adb8-762c-8a34-68ae2626b554/7",
  "deckHref": "/decks/019de075-adb8-762c-8a34-68ae2626b554",
  "deckJsonHref": "/decks/019de075-adb8-762c-8a34-68ae2626b554.json",
  "deckAnchorHref": "/decks/019de075-adb8-762c-8a34-68ae2626b554#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.13,
        "x": 0.118,
        "y": 0.185
      },
      "kind": "image",
      "text": "CARVYKTI logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5abb019a-ad78-4755-9ae7-73bba985e71f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.53,
        "y": 0.45
      },
      "kind": "list",
      "text": "Contracted with Novartis in April 2023; Results from CARTITUDE-4 demonstrated statistically significant improvement; Submissions made to U.S. and EU regulatory agencies in 2Q 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bdf0cc1-4d8b-4b46-a33a-bb0be7b5758e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.12,
        "y": 0.8
      },
      "kind": "list",
      "text": "U.S. FDA has accepted cilta-cel sBLA; Enrollment of CARTITUDE-6 expected to begin in 2H 2023; Enrollment of CARTITUDE-5 to be completed by end of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1f5140d-ec80-4df0-ab3a-de4da0168eeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.38,
        "x": 0.12,
        "y": 0.45
      },
      "kind": "list",
      "text": "Approved by the U.S. FDA for the treatment of 5L+ MM in Feb. 2022; Granted conditional marketing authorization by the European Commission for 4L+ MM in May 2022; Approved by Japan's MHLW for 4L+ MM in Sep 2022; Long-term results from CARTITUDE-1...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9c27215-b3eb-43bc-bf26-c5272e403a65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.25,
        "y": 0.19
      },
      "kind": "paragraph",
      "text": "Submissions Were Accepted by U.S. FDA and EMA for Expanded Use of CARVYKTI®",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ef69b0e-aa02-4d6e-bd2d-8eb07883be10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.106,
        "y": 0.106
      },
      "kind": "title",
      "text": "Near-Term Label Expansion Potential: Cilta-cel",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9d1c3ed-dcbd-4493-966d-b78f5812365b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "84f36a56-d861-44ea-8f79-cc2ee30101cf",
      "evidence": "The slide explicitly contrasts 'Heavily Pre-Treated' vs 'Earlier Lines' to show strategic progression.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 7,
      "from": 6,
      "beatId": "dc206db6-781b-4463-87f2-42a43f50929a",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The updated clinical profile for Cilta-cel and near-term label expansion potential are discussed, addressing challenges and progress.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "33f76588-e3d7-4ba4-82dc-e0f8db9d19fe",
      "evidence": "The near-term label expansion potential for Cilta-cel is discussed, implying the cost of inaction.",
      "position": 0,
      "objective": "What are the consequences of not expanding Cilta-cel's label?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}